PAR14 EVALUATION OF ACCESS TO HIGH-COST MEDICINES IN AUSTRALIA USING NATIONAL CLAIMS DATA  by Lu, CY et al.
A28 Abstracts
OBJECTIVE: To evaluate the direct medical cost in the man-
agement of rheumatoid arthritis (RA) as well as the extent of
resource use in current practice from the perspective of public
health organization in Hong Kong. METHODS: This study was
a retrospective design. Subjects recruited must have RA diag-
nosed and attended the follow-up visits, receiving RA treatment
in the Prince of Wales Hospital (PWH) between the period of 1st
January 2002 to 31st December 2002. Data was collected by
medical chart review. The direct medical costs included inpatient
care, outpatient visits, laboratory monitoring, radiological pro-
cedure, drug cost and side effects management. RESULTS: A
total of 147 patients were included in our study. The average 
age and the duration of disease of our subjects were 54.7 years
old (SD: 10.9) and 12.6 year (SD: 7.0) respectively. The annual
direct medical cost per each RA patient was HK $18,657 (US $1
= HK $7.8). The inpatient care contributed 43.8% of the total,
which was the highest. The cost for laboratory monitoring 
was the second (19.2%) where the outpatient cost ranked the
third (15.4%). The cost for RA-related drugs accounted for
9.8%. The cost for the management of the side effects shared
3.1% of the total. Based on a local epidemiological study, the
RA prevalence rate was 0.3%. The annual direct medical cost
for the management of RA in Hong Kong would be HK $443
million, which shared 1.4% of the total health care budget in
2002. CONCLUSION: This study demonstrated that RA was a
signiﬁcant economic burden to the health care budget of Hong
Kong.
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Effective high-cost medicines, for example, tumour necrosis
factor inhibitors (TNFIs), are subsidised in Australia under the
Pharmaceutical Beneﬁts Scheme (PBS), but access is restricted to
ensure cost-effective use. An application for initial or continuing
access to TNFIs requires detailed information on each patient,
including laboratory markers and previous pharmacotherapies.
OBJECTIVES: To examine the access to TNFIs in Australia for
treating rheumatoid arthritis. METHODS: Both aggregated, and
individual de-identiﬁed information were requested from the
Health Insurance Commission (HIC) including the number of
applications received and approved, patient demographics, use
of other disease-modifying anti-rheumatic drugs, changes in clin-
ical outcomes, the time interval between application and deci-
sion to approve, and geographical pattern of usage. Prescription
and expenditure data (August 2003–March 2005) for the TNFIs,
etanercept, inﬂiximab, and adalimumab, were examined.
RESULTS: The detailed clinical information submitted with the
applications was not captured by the HIC database. A total of
19,629 prescriptions was reimbursed: etanercept (15,675), inﬂix-
imab (570), and adalimumab (3384), at a total cost of
AUD$43.5 million. The uptake of these agents was considerably
lower than expected. The number of patients using a TNFI under
the PBS could only be approximated from these aggregated
ﬁgures—more than 2,000 patients had been commenced on
TNFIs. The proportion of patients that were approved to 
continue or switch between TNFIs was not available. CON-
CLUSION: The HIC is positioned to capture subsidised pre-
scription-drug usage and clinical outcome data on a national
basis. Unfortunately, it is impossible to access detailed data.
Information on utilisation of TNFIs is far from adequate. Com-
prehensive drug usage and patient health outcome data need to
be accessible in order to deﬁne the most appropriate use and
access to these agents. Update of, and arrangements for access
to the HIC database are encouraged.
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Access to high-cost medicines such as to the tumour necrosis
factor inhibitors (TNFIs) for the treatment of rheumatoid arthri-
tis is tightly regulated under Australia’s Pharmaceutical Beneﬁts
Scheme (PBS) to ensure their cost-effective use. OBJECTIVES:
To explore stakeholders’ perceptions and experiences associated
with the restricted access to TNFIs and the process of collabo-
ration between key stakeholders who formulated the access 
criteria. METHODS: Thirty-three, in-depth semi-structured
interviews were conducted between 2004 and 2005. Participants
included rheumatologists, patients treated with TNFIs, consumer
representatives, government health advisors, public servants, and
representatives from pharmaceutical companies involved in for-
mulating and implementing the access restrictions. Participants
were asked to comment on the access restrictions that have
applied since August 2003, and their views on the collaboration
between stakeholders were collected. Interviews were recorded,
transcribed verbatim, and thematically analysed. RESULTS: The
principle of “controlled access” to TNFIs was in general
accepted by all, despite the different perspectives each person
represented. However, there were concerns regarding some of the
speciﬁc PBS criteria. Overall, the collaborative approach that
was taken to formulate the criteria for access to TNFIs was per-
ceived by key stakeholders as a valuable advance and has set a
new paradigm for subsequent PBS subsidy decisions. However,
a wider and more transparent decision-making process, and a
more structured and continuing communication between stake-
holders were judged desirable. Some degree of ﬂexibility with
respect to physician prescribing, and a need to increase educa-
tion to health care professionals and the community were pro-
posed. CONCLUSION: Targeting access to high-cost medicines
through a national subsidy system was agreed to be practical and
equitable. Increased transparency, communication and education
were identiﬁed as the main elements needed to secure support of
the ﬁnal access criteria by all involved. In order to conﬁrm these
primary themes, further interviews are being undertaken until
data saturation is achieved.
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Data from randomized controlled trials (RCTs) are often used in
economic evaluations when estimating cost-effectiveness. The
data generated from RCTs represent ideal experimental condi-
tions (efﬁcacy) and the applicability of this data to real world
settings (effectiveness) may be questionable. OBJECTIVES: 1) To
conduct an economic evaluation of etanercept (a competitive
inhibitor of TNF-a) use in rheumatoid arthritis patients in
Canada, and 2) To compare the results of a cost-effectiveness
analysis conducted with efﬁcacy data obtained from a RCT, to
results derived by using effectiveness data obtained from com-
munity-based clinical practice. METHODS: The data used to
perform the analyses were obtained from a trans Canadian com-
munity-based cohort study conducted between 1999 and 2003.
A cost-utility analysis was preformed and incremental cost-effec-
